We are live on ! Find out more
JANX icon

Janux Therapeutics
JANX

155 hedge funds and large institutions have $1.87B invested in Janux Therapeutics in 2024 Q2 according to their latest regulatory filings, with 55 funds opening new positions, 58 increasing their positions, 33 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

189% more first-time investments, than exits

New positions opened: 55 | Existing positions closed: 19

76% more repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 33

28% more funds holding

Funds holding: 121 → 155 (+34)

18% more capital invested

Capital invested by funds: $1.59B → $1.87B (+$279M)

4.3% more ownership

Funds ownership: 81.95% → 86.26% (+4.3%)

8% less call options, than puts

Call options by funds: $4.12M | Put options by funds: $4.46M

50% less funds holding in top 10

Funds holding in top 10: 4 → 2 (-2)

Holders
155
Holders Change
+34
Holders Change %
+28.1%
% of All Funds
2.24%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
55
Increased
58
Reduced
33
Closed
19
Calls
$4.12M
Puts
$4.46M
Net Calls
-$335K
Net Calls Change
+$2.56M

Top Buyers

Rank Fund Capital Flow
1
PBA
Paradigm Biocapital Advisors
New York
+$73.5M
2
EC
EcoR1 Capital
California
+$69M
3
State Street
State Street
Massachusetts
+$47M
4
VPC
Vestal Point Capital
New York
+$34M
5
BlackRock
BlackRock
New York
+$30.5M

Top Sellers

Rank Fund Capital Flow
1
BI
BVF Inc
California
-$116M
2
O
OrbiMed
New York
-$60.8M
3
RI
RTW Investments
New York
-$37.6M
4
Citadel Advisors
Citadel Advisors
Florida
-$37.2M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$21M
Name Holding Trade Value Shares
Change 		Change in
Stake
OAC
76
OMERS Administration Corp
Ontario, Canada
$817K +$916K +19,500 New
Two Sigma Advisers
77
Two Sigma Advisers
New York
$808K -$2.99M -63,700 -77%
JP Morgan Chase
78
JP Morgan Chase
New York
$805K -$6.1K -130 -0.7%
JF
79
Jump Financial
Illinois
$758K +$113K +2,409 +15%
MIM
80
MetLife Investment Management
New Jersey
$685K +$342K +7,288 +80%
Citigroup
81
Citigroup
New York
$653K -$1.22M -25,977 -62%
CF
82
Corebridge Financial
Texas
$632K +$708K +15,085 New
Walleye Capital
83
Walleye Capital
New York
$603K +$676K +14,399 New
PA
84
Profund Advisors
Maryland
$598K +$670K +14,274 New
Deutsche Bank
85
Deutsche Bank
Germany
$520K +$268K +5,699 +85%
Victory Capital Management
86
Victory Capital Management
Texas
$512K +$574K +12,220 New
GGHC
87
Gilder Gagnon Howe & Co
New York
$484K -$1.74K -37 -0.3%
New York State Common Retirement Fund
88
New York State Common Retirement Fund
New York
$484K +$202K +4,307 +59%
Franklin Resources
89
Franklin Resources
California
$483K +$542K +11,541 New
PL
90
Parkwood LLC
Ohio
$477K +$535K +11,390 New
Mirae Asset Global ETFs Holdings
91
Mirae Asset Global ETFs Holdings
Hong Kong
$458K +$518K +11,043 New
AGM
92
Alpine Global Management
New York
$425K +$476K +10,142 New
Qube Research & Technologies (QRT)
93
Qube Research & Technologies (QRT)
United Kingdom
$420K +$471K +10,034 New
KCM
94
Kennedy Capital Management
Missouri
$418K +$469K +9,980 New
NIM
95
NEOS Investment Management
Connecticut
$407K +$457K +9,723 New
HM
96
Harvest Management
New York
$406K +$455K +9,700 New
Invesco
97
Invesco
Georgia
$404K +$86.7K +1,846 +24%
Allianz Asset Management
98
Allianz Asset Management
Germany
$398K +$446K +9,500 New
Wells Fargo
99
Wells Fargo
California
$377K +$136K +2,907 +48%
SEI Investments
100
SEI Investments
Pennsylvania
$375K -$8.26K -176 -2%
2 3
4
5 6

JANX Hedge Fund Activity: Q2 2024 in Review

155 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Janux Therapeutics (JANX) for Q2 2024, worth a combined $1.87B — up 18% from $1.59B a quarter earlier.

Buyers outnumbered sellers: 55 funds opened new JANX positions and 19 closed out — a net gain of 36 holders — while 58 added to existing stakes and 33 trimmed.

The largest buyer was Paradigm Biocapital Advisors, opening a new position worth an estimated $73.5M. The largest seller was BVF Inc, cutting an estimated $116M.

  • 155 institutional investors held Janux Therapeutics (JANX) as of Q2 2024, up from 121 in Q1 2024.
  • Funds reported $1.87B of Janux Therapeutics stock for Q2 2024, up 18% quarter-over-quarter.
  • 55 funds opened new Janux Therapeutics positions in Q2 2024 and 19 closed out, a net change of +36 holders.
  • The largest Janux Therapeutics buyer in Q2 2024 was Paradigm Biocapital Advisors, an estimated $73.5M added.
  • The largest Janux Therapeutics seller in Q2 2024 was BVF Inc, an estimated $116M sold.

Based on aggregated 13F filings for Q2 2024.